Table 5. Epidemiological and virological characteristics of the 7 antiretroviral-naïve and the 9 antiretroviral-experienced patients infected by HIV-1M variants harboring drug resistance mutations.
| # | ART | Population | HIV-1Mvariant | Gender | Riskpractice | Samplingyear | HIV VL(log) | TDR-PI | TDR-NRTI | TDR-NNRTI |
| 1 | Naïve | Adult | B | F | Htsex | 1999 | 2.5 | M46L, L90M | NA | NA |
| 2 | Naïve | Adult | B | F | NA | 1999 | 4.3 | M46L, I84V | NA | NA |
| 3 | Naïve | Adult | C | F | Htsex | 1999 | 1.8 | M46I | NA | NA |
| 4 | Naïve | Adult | CRF02_AG | F | NA | 2005 | 3.6 | – | M184V | – |
| 5 | Naïve | Adult | CRF11_cpx | F | Htsex | 2006 | 2.9 | – | M184V | Y188L |
| 6 | Naïve | Adult | A1 | F | Htsex | 2007 | 2.7 | M46L | – | – |
| 7 | Naïve | Pediatric | CRF02_AG | M | Vertical | 2007 | NA | M46L | – | – |
| 8 | Treated | Adult | B | F | Htsex | 1999 | 2.3 | M46L | NA | NA |
| 9 | Treated | Adult | B | F | Htsex | 1999 | 2.3 | M46L, L90M | NA | NA |
| 10 | Treated | Adult | B | F | Htsex | 1999 | 2.3 | M46L, I84V, L90M | NA | NA |
| 11 | Treated | Adult | CRF02_AG | F | Htsex | 2003 | 4.0 | F53L, I84V, L90M | M184V | K103N |
| 12 | Treated | Adult | F2 | M | Htsex | 2006 | NA | – | – | V106I |
| 13 | Treated | Adult | D | M | Htsex | 2008 | 5.0 | – | – | V90I |
| 14 | Treated | Pediatric | CRF02_AG | F | Vertical | 2009 | NA | – | M184V | – |
| 15 | Treated | Adult | CRF02_AG | M | Htsex | 2009 | 6.0 | – | – | K103N |
| 16 | Treated | Pediatric | CRF02_AG | F | Vertical | 2010 | NA | M46L, I84V | L74V, Y115F, M184V | K103N, G190A |
#, number of patient; ART, antiretroviral treatment; VL, viral load; TDR, transmitted drug resistance mutations; PI, protease inhibitors; NRTI, nucleoside reverse transcriptase inhibitors; NNRTI, non-nucleoside reverse transcriptase inhibitors; F, female; M, male; Htsex, heterosexual; NA, data not available; Dash, no mutation found.